Literature DB >> 22591781

Day-to-day variability in spot urine protein-creatinine ratio measurements.

Chetana N Naresh1, Andrew Hayen, Jonathan C Craig, Steven J Chadban.   

Abstract

BACKGROUND: Accurate measurement of proteinuria is important in the diagnosis and management of chronic kidney disease (CKD). The reference standard test, 24-hour urinary protein excretion, is inconvenient and vulnerable to collection errors. Spot urine protein-creatinine ratio (PCR) is a convenient alternative and is in widespread use. However, day-to-day variability in PCR measurements has not been evaluated. STUDY
DESIGN: Prospective cohort study of day-to-day variability in spot urine PCR measurement. SETTING & PARTICIPANTS: Clinically stable outpatients with CKD (n = 145) attending a university hospital CKD clinic in Australia between July 2007 and April 2010. INDEX TEST: Spot urine PCR. OUTCOMES: Spot PCR variability was assessed and repeatability limits were determined using fractional polynomials. MEASUREMENTS: Spot PCRs were measured from urine samples collected at 9:00 am on consecutive days and 24-hour urinary protein excretion was collected concurrently.
RESULTS: Paired results were analyzed from 145 patients: median age, 56 years; 59% men; and median 24-hour urinary protein excretion, 0.7 (range, 0.06-35.7) g/d. Day-to-day variability was substantial and increased in absolute terms, but decreased in relative terms with increasing baseline PCR. For patients with a low baseline PCR (20 mg/mmol [177 mg/g]), a change greater than ±160% (repeatability limits, 0-52 mg/mmol [0-460 mg/g]) is required to indicate a real change in proteinuria status with 95% certainty, whereas for those with a high baseline PCR (200 mg/mmol [1,768 mg/g]), a change of ±50% (decrease to <100 mg/mmol [<884 mg/g] or increase to >300 mg/mmol [>2,652 mg/g]) represents significant change. LIMITATIONS: These study results need to be replicated in other ethnic groups.
CONCLUSIONS: Changes in PCR observed in patients with CKD, ranging from complete resolution to doubling of PCR values, could be due to inherent biological variation and may not indicate a change in disease status. This should be borne in mind when using PCR in the diagnosis and management of CKD.
Copyright © 2012 National Kidney Foundation, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22591781     DOI: 10.1053/j.ajkd.2012.04.010

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  12 in total

1.  Relationship between eGFR Decline and Hard Outcomes after Kidney Transplants.

Authors:  Philip A Clayton; Wai H Lim; Germaine Wong; Steven J Chadban
Journal:  J Am Soc Nephrol       Date:  2016-04-08       Impact factor: 10.121

2.  Five-year kidney outcomes of bariatric surgery differ in severely obese adolescents and adults with and without type 2 diabetes.

Authors:  Petter Bjornstad; Edward Nehus; Todd Jenkins; Mark Mitsnefes; Marva Moxey-Mims; John B Dixon; Thomas H Inge
Journal:  Kidney Int       Date:  2020-02-03       Impact factor: 10.612

3.  Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series.

Authors:  Frank B Cortazar; David E Leaf; Charles T Owens; Karen Laliberte; William F Pendergraft; John L Niles
Journal:  BMC Nephrol       Date:  2017-02-01       Impact factor: 2.388

4.  Clinical outcomes associated with albuminuria in central Australia: a cohort study.

Authors:  Rebecca Ritte; Joanne Luke; Craig Nelson; Alex Brown; Kerin O'Dea; Alicia Jenkins; James D Best; Robyn McDermott; Mark Daniel; Kevin Rowley
Journal:  BMC Nephrol       Date:  2016-08-05       Impact factor: 2.388

5.  Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease.

Authors:  Tarec K Elajami; Abdulhamied Alfaddagh; Dharshan Lakshminarayan; Michael Soliman; Madhuri Chandnani; Francine K Welty
Journal:  J Am Heart Assoc       Date:  2017-07-14       Impact factor: 5.501

6.  Predictive value of spot versus 24-hour measures of proteinuria for death, end-stage kidney disease or chronic kidney disease progression.

Authors:  Tracey Ying; Philip Clayton; Chetana Naresh; Steven Chadban
Journal:  BMC Nephrol       Date:  2018-03-07       Impact factor: 2.388

7.  Limited Reliability of the Spot Urine Protein/Creatinine Ratio in the Longitudinal Evaluation of Patients With Lupus Nephritis.

Authors:  Ganesh Shidham; Isabelle Ayoub; Dan Birmingham; Paul Hebert; Brad Rovin; Betty Diamond; David Wofsy; Lee Hebert
Journal:  Kidney Int Rep       Date:  2018-04-27

8.  Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy.

Authors:  Christine Barrett; Lisa C Willcocks; Rachel B Jones; Ruth M Tarzi; Robert B Henderson; Gengqian Cai; Sophie I Gisbert; Alexandra S Belson; Caroline O Savage
Journal:  Nephrol Dial Transplant       Date:  2020-04-01       Impact factor: 5.992

9.  Consecutive first-morning urine samples to measure change in the albumin-to-creatinine ratio: a pilot study of a home urine collection protocol.

Authors:  Jessica M Sontrop; Amit X Garg; Lihua Li; Kerri Gallo; Virginia Schumann; Jennifer Winick-Ng; William F Clark; Matthew A Weir
Journal:  Can J Kidney Health Dis       Date:  2016-02-01

Review 10.  Monitoring Immune Responses in IgA Nephropathy: Biomarkers to Guide Management.

Authors:  Haresh Selvaskandan; Sufang Shi; Sara Twaij; Chee Kay Cheung; Jonathan Barratt
Journal:  Front Immunol       Date:  2020-10-06       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.